cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group.
A dose of 50 mg/m2 of cis-dichlorodiammineplatinum(II) was administered iv every 3 weeks to 25 patients with squamous cell carcinoma of the cervix and to 34 patients with adenocarcinoma of the ovary. All patients had advanced or recurrent disease. Eleven of the 25 patients (44%) with cervical carcinoma had an objective response while ten of 34 patients (29%) with ovarian carcinoma demonstrated an objective response. Toxic effects were frequent but tolerable, with no drug-related deaths and only minimal drug-related nephrotoxicity, except in one patient. Myelosuppression was more frequent in the more heavily previously treated ovarian carcinoma patients. cis-Dichlorodiammineplatinum(II) thus appears to be a highly active single agent in the treatment of squamous cell carcinoma of the cervix and adenocarcinoma of the ovary.
D000230:Adenocarcinoma / Q000188:drug therapy; D001853:Bone Marrow / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002945:Cisplatin / Q000627:therapeutic use* / Q000633:toxicity; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000187:drug effects; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012075:Remission, Spontaneous; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy
D002945:Cisplatin